Last reviewed · How we verify
transdermal therapeutic system- melatonin.
Melatonin binds to melatonin receptors (MT1 and MT2) to regulate circadian rhythm and promote sleep.
Melatonin binds to melatonin receptors (MT1 and MT2) to regulate circadian rhythm and promote sleep. Used for Insomnia, Circadian rhythm sleep disorders, Sleep disturbances.
At a glance
| Generic name | transdermal therapeutic system- melatonin. |
|---|---|
| Also known as | TDM, melatonin sleep patch from Respro Labs ™ (7 mg/8hr). |
| Sponsor | Ain Shams University |
| Drug class | Melatonin receptor agonist |
| Target | MT1 and MT2 melatonin receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | FDA-approved |
Mechanism of action
Melatonin is an endogenous hormone that acts as a circadian rhythm regulator by binding to melatonin receptors in the suprachiasmatic nucleus and other tissues. The transdermal therapeutic system formulation delivers melatonin across the skin to maintain steady-state plasma levels, enhancing sleep onset and quality. This mechanism helps restore normal sleep-wake cycles in patients with circadian rhythm disorders or insomnia.
Approved indications
- Insomnia
- Circadian rhythm sleep disorders
- Sleep disturbances
Common side effects
- Headache
- Dizziness
- Skin irritation at application site
- Drowsiness
Key clinical trials
- Transdermal Nicotine and Melatonin Patches for Postoperative Pain Relief (PHASE4)
- Transdermal Fentanyl and Melatonin Patches for Postoperative Pain Relief
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: